Literature DB >> 23243491

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.

James G Kublin1, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath, Lawrence Corey.   

Abstract

The HIV Vaccine Trials Network (HVTN) is an international collaboration of scientists and educators facilitating the development of HIV/AIDS preventive vaccines. The HVTN conducts all phases of clinical trials, from evaluating experimental vaccines for safety and immunogenicity, to testing vaccine efficacy. Over the past decade, the HVTN has aimed to improve the process of designing, implementing and analyzing vaccine trials. Several major achievements include streamlining protocol development while maintaining input from diverse stakeholders, establishing a laboratory program with standardized assays and systems allowing for reliable immunogenicity assessments across trials, setting statistical standards for the field and actively engaging with site communities. These achievements have allowed the HVTN to conduct over 50 clinical trials and make numerous scientific contributions to the field.

Entities:  

Year:  2012        PMID: 23243491      PMCID: PMC3521567          DOI: 10.4155/cli.12.8

Source DB:  PubMed          Journal:  Clin Investig (Lond)        ISSN: 2041-6792


  28 in total

1.  Provision of treatment in HIV-1 vaccine trials in developing countries.

Authors:  Daniel W Fitzgerald; Jean William Pape; Judith N Wasserheit; George W Counts; George W Counts; Lawrence Corey
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

2.  Safety profile of recombinant canarypox HIV vaccines.

Authors:  Guy de Bruyn; Anthony J Rossini; Ya-Lin Chiu; Drienna Holman; Marnie L Elizaga; Sharon E Frey; Donald Burke; Thomas G Evans; Lawrence Corey; Michael C Keefer
Journal:  Vaccine       Date:  2004-01-26       Impact factor: 3.641

3.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.

Authors:  Glenda Gray; Susan Buchbinder; Ann Duerr
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

5.  The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Biostatistics       Date:  2007-08-17       Impact factor: 5.899

6.  Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Authors:  Paul A Goepfert; Georgia D Tomaras; Helen Horton; David Montefiori; Guido Ferrari; Mark Deers; Gerald Voss; Marguerite Koutsoukos; Louise Pedneault; Pierre Vandepapeliere; M Juliana McElrath; Paul Spearman; Jonathan D Fuchs; Beryl A Koblin; William A Blattner; Sharon Frey; Lindsey R Baden; Clayton Harro; Thomas Evans
Journal:  Vaccine       Date:  2006-08-10       Impact factor: 3.641

7.  HIV-1 vaccines and adaptive trial designs.

Authors:  Lawrence Corey; Gary J Nabel; Carl Dieffenbach; Peter Gilbert; Barton F Haynes; Margaret Johnston; James Kublin; H Clifford Lane; Giuseppe Pantaleo; Louis J Picker; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2011-04-20       Impact factor: 17.956

8.  Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.

Authors:  Cristine J Cooper; Barbara Metch; Joan Dragavon; Robert W Coombs; Lindsey R Baden
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

9.  Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

Authors:  P B Gilbert; Y-L Chiu; M Allen; D N Lawrence; C Chapdu; H Israel; D Holman; M C Keefer; M Wolff; S E Frey
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

10.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Authors:  Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins
Journal:  Nat Med       Date:  2011-02-27       Impact factor: 53.440

View more
  6 in total

Review 1.  Vaccine development for syphilis.

Authors:  Karen V Lithgow; Caroline E Cameron
Journal:  Expert Rev Vaccines       Date:  2016-07-18       Impact factor: 5.217

Review 2.  Novel directions in HIV-1 vaccines revealed from clinical trials.

Authors:  Jean-Louis Excler; Georgia D Tomaras; Nina D Russell
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

Review 3.  Lessons learned from HIV vaccine clinical efficacy trials.

Authors:  Tracey A Day; James G Kublin
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

4.  Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials.

Authors:  Robert K Langat; Bashir Farah; Jackton Indangasi; Simon Ogola; Gloria Omosa-Manyonyi; Omu Anzala; Jean Bizimana; Emmanuel Tekirya; Caroline Ngetsa; Moses Silwamba; Enoch Muyanja; Paramesh Chetty; Maureen Jangano; Nancy Hills; Jill Gilmour; Len Dally; Josephine H Cox; Peter Hayes
Journal:  Afr J Lab Med       Date:  2021-02-17

Review 5.  Leveraging lessons learned from the COVID-19 pandemic for HIV.

Authors:  Thomas Calder; Tina Tong; Dale J Hu; Jerome H Kim; Karen L Kotloff; Richard A Koup; Mary A Marovich; M Juliana McElrath; Sarah W Read; Merlin L Robb; Philip O Renzullo; M Patricia D'Souza
Journal:  Commun Med (Lond)       Date:  2022-08-29

6.  Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence.

Authors:  Suzanne Day; Meredith Blumberg; Thi Vu; Yang Zhao; Stuart Rennie; Joseph D Tucker
Journal:  J Int AIDS Soc       Date:  2018-10       Impact factor: 5.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.